|
Re: Method of preventing adverse effects by GLP-1
|
1
|
Mannkind
|
Feb 19, 2013 01:36PM
|
|
Re: Method of preventing adverse effects by GLP-1
|
1
|
Mannkind
|
Feb 19, 2013 04:00PM
|
|
Re: What's New in ADA's Latest Diabetes Guidelines?
|
1
|
Mannkind
|
Feb 19, 2013 05:04PM
|
|
Re: What's New in ADA's Latest Diabetes Guidelines?
|
2
|
Mannkind
|
Feb 19, 2013 07:11PM
|
|
Re: Job opening
|
1
|
Mannkind
|
Feb 19, 2013 10:06PM
|
|
Cowen and Company
|
1
|
Mannkind
|
Feb 20, 2013 11:51AM
|
|
Re: Cowen and Company
|
|
Mannkind
|
Feb 20, 2013 04:33PM
|
|
Re: Cowen and Company
|
|
Mannkind
|
Feb 20, 2013 05:07PM
|
|
Re: Cowen and Company
|
|
Mannkind
|
Feb 20, 2013 05:10PM
|
|
Re: Cowen and Company
|
2
|
Mannkind
|
Feb 20, 2013 06:14PM
|
|
Diabetes Summit 2013 Organized by GTC Company
|
|
Mannkind
|
Feb 21, 2013 09:54AM
|
|
Biopharmaceutical Companies Developing Insulin Pills May Bring High Profits
|
|
Mannkind
|
Feb 21, 2013 09:57AM
|
|
Should MannKind Investors Bank on a Partnership?
|
|
Mannkind
|
Feb 21, 2013 03:03PM
|
|
MannKind and Ariad Pharma Under Review: Biotech Companies Receive Drug Approvals
|
1
|
Mannkind
|
Feb 22, 2013 09:41AM
|
|
3 Bio-Pharmaceuticals Insiders Love
|
|
Mannkind
|
Feb 22, 2013 12:49PM
|
|
MannKind Trivia: Who Likes Word Problems
|
|
Mannkind
|
Feb 23, 2013 10:10PM
|
|
Roundtable: 5 Disruptive Technologies Leading the Next Medical Revolution
|
3
|
Mannkind
|
Feb 26, 2013 03:36PM
|
|
Patient Transitioning From Exubera®
|
2
|
Mannkind
|
Feb 26, 2013 06:02PM
|
|
Re: Patient Transitioning From Exubera®
|
|
Mannkind
|
Feb 26, 2013 07:49PM
|
|
Re: Patient Transitioning From Exubera®
|
|
Mannkind
|
Feb 27, 2013 12:08PM
|
